Back to All Combinations
NRAS Mutated
Intermediate PrognosisGenes Involved
NRAS
Treatment Implications
Functionally equivalent to KRAS. Precludes anti-EGFR.
Recommended Treatments
FOLFOX + Bevacizumab
FOLFIRI + Bevacizumab
FOLFOXIRI + Bevacizumab
Treatments to Avoid
Cetuximab
Panitumumab
Study References
PRIME, FIRE-3
Key Statistics
5.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Must test both KRAS and NRAS.
Information
Category: RAS Pathway
Evidence Level: Level 1
Last Updated: Dec 7, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.